Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347315 · ClinicalTrials.gov registry record · NA

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

A NA study of Mild Cognitive Impairment, sponsored by Société des Produits Nestlé (SPN).

Recruiting
Registry status
NA
Development phase
380
Enrollment target
20
Study locations

NCT06347315: Recruiting NA study of Mild Cognitive Impairment, sponsored by Société des Produits Nestlé (SPN).

NCT06347315 is a NA study of Mild Cognitive Impairment that is actively recruiting participants, run by Société des Produits Nestlé (SPN). The registered enrollment target is 380 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347315, a NA study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Société des Produits Nestlé (SPN).

RECRUITING
Registry status
NA
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

Conditions Studied

Mild Cognitive Impairment

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT BrainXpert

Study Locations (20)

Other

  • Hôpital Pierre Wertheimer - Bron
  • CHU de Montpellier - Hôpital Gui de Chauliac - Montpellier
  • CHU de Nantes - Hôpital Nord Laennec - Nantes
  • CHU de Toulouse - Gerontopole - Toulouse
  • Klinikum Bayreuth GmbH - Klinik Hohe Warte - Bayreuth
  • Studienzentrum für Neurologie und Psychiatrie - Böblingen
  • Neuro Centrum Science GmbH - Erbach im Odenwald
  • Universitaetsmedizin Ulm - Ulm
  • Foundation Institute G.Giglio - Cefalù
  • IRCCS Ospedale Policlinico San Martino - Genova
  • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" - Palermo
  • AOU Policlinico Umberto I - Sapienza Università di Roma - Roma
  • Azienda Ospedaliera SantAndrea - Roma
  • Laboratory of Neuropsyichiatry, Fondazione Santa Lucia IRCCS - Roma
  • Policlinico Universitario Agostino Gemelli - Roma
  • AO Card. G. Panico - Tricase
  • Hospital Universitario del Vinalopó - Alicante
  • Fundaciò ACE - Barcelona

Florida

  • Stein Gerontological Institute Inc - Miami

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2024-05-24
Est. Completion 2027-12-15
Phase NA
Société des Produits Nestlé (SPN)

53 total trials

What NCT06347315 shows while recruiting

NCT06347315 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06347315 names 20 study sites across 3 states, led by Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT06347315 about?

NCT06347315 is a clinical study titled "Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)". Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

What is the current status of trial NCT06347315?

This trial is currently recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2024-05-24. Estimated completion is 2027-12-15.

What conditions does trial NCT06347315 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT06347315?

The interventions under investigation include: Placebo (OTHER), BrainXpert (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06347315?

This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347315 being conducted?

This trial has 20 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06347315's enrollment target sits among peer trials

380 25th of 205 higher than 181 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04560673 · 380 participants · Phase 2

    Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

  • NCT04777357 · 380 participants · Phase 3

    A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

  • NCT04821154 · 380 participants

    Persona Revision Knee System Outcomes

  • NCT05102019 · 380 participants · NA

    Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06347315

Source: ClinicalTrials.gov NCT06347315, the US trial registry maintained by the National Library of Medicine. NCT06347315 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.